Association of neutrophil-to-lymphocyte ratio with clinical outcomes after percutaneous coronary intervention

Authors:

Abstract
Aims: Inflammation contributes significantly to coronary artery disease (CAD). The neutrophil-to-lymphocyte ratio (NLR) has emerged as a readily available biomarker reflecting both inflammatory and immune cells’ activity, potentially enhancing risk stratification of patients with CAD. This study evaluates the clinical impact of baseline NLR in patients undergoing percutaneous coronary intervention (PCI) for both chronic coronary syndrome and acute coronary syndrome (ACS). Methods and results: We conducted a retrospective analysis of patients undergoing PCI at Mount Sinai Hospital between 2012 and 2022. Patients were stratified into NLR quartiles and outcomes were analysed using Cox regression models. The primary endpoint was major adverse cardiovascular events (MACEs) at 1-year follow-up, including all-cause death, myocardial infarction (MI), and stroke. A total of 7287 patients were included in the study. Age, male sex, comorbidities, high-sensitivity C-reactive protein, and complexity of PCI tended to be higher in the highest NLR quartiles. At 1 year, MACE incidence increased across NLR quartiles, from 5.1% (1st quartile) to 9.3% (4th quartile) (P for trend = 0.004). Compared with the 1st quartile, the 4th NLR quartile (NLR > 5.0) was associated with increased adjusted risks of MACE [adjusted hazard ratio (adjHR) 1.52, 95% CI 1.12–2.05], all-cause death (adjHR 1.71, 95% CI 1.10–2.65), MI (adjHR 1.53, 95% CI 1.00–2.35), and bleeding (adjHR 2.01, 95% CI 1.50–2.70). Ischaemic risk associated with high NLR was more pronounced in patients presenting with ACS and chronic kidney disease (CKD). Conclusion: Baseline NLR is associated with adverse cardiovascular outcomes in CAD patients undergoing PCI. Assessment of NLR could enhance risk stratification particularly in patients with ACS and CKD.
Funding Information
  • German Heart Foundation (S/06/23)
  • AngioWave
  • Boehringer Ingelheim
  • CellProthera
  • Cereno Scientific
  • High Enroll
  • Level Ex
  • McKinsey
  • Medscape Cardiology
  • NirvaMed
  • PhaseBio
  • PLx Pharma
  • American Heart Association New York City
  • AngioWave
  • Broadview Ventures
  • GlaxoSmithKline
  • Hims
  • SFJ
  • Youngene;
  • Acesion Pharma
  • Assistance publique-Hôpitaux de Paris
  • Baim Institute for Clinical Research
  • Harvard Clinical Research Institute
  • PORTICO
  • PEITHO
  • Cleveland Clinic
  • Contego Medical
  • Mayo Clinic
  • Mount Sinai School of Medicine
  • ENVISAGE
  • ABILITY-DM
  • ALLAY-HF
  • Alleviant Medical
  • Rutgers University
  • NIH
  • MINT
  • American College of Cardiology
  • Clinical Trials and News
  • ACC Accreditation Oversight Committee
  • Sanofi
  • Bristol-Myers Squibb clopidogrel litigation
  • Baim Institute for Clinical Research
  • Harvard Clinical Research Institute
  • RE-DUAL PCI
  • Boehringer Ingelheim; AEGIS-II
  • Belvoir Publications
  • Harvard Heart Letter
  • Canadian Medical and Surgical Knowledge Translation Research Group
  • CSL Behring
  • AHA lecture
  • Cowen and Company
  • Duke Clinical Research Institute
  • PRONOUNCE
  • HMP Global
  • Journal of Invasive Cardiology
  • Journal of the American College of Cardiology
  • K2P
  • Level Ex
  • Medtelligence
  • ReachMD
  • MJH Life Sciences
  • Oakstone CME
  • Comprehensive Review of Interventional Cardiology
  • Piper Sandler
  • Population Health Research Institute
  • COMPASS
  • Bayer
  • WebMD
  • WILEY
  • Clinical Cardiology
  • Sotagliflozin
  • Brigham and Women’s Hospital
  • Abbott
  • Acesion Pharma
  • Afimmune
  • Aker BioMarine
  • Alnylam
  • Amarin
  • AstraZeneca
  • Bayer
  • Beren
  • Boston Scientific
  • Cardax
  • CellProthera
  • Cereno Scientific
  • CinCor
  • Cleerly
  • CSL Behring
  • Eisai
  • Ethicon
  • Faraday Pharmaceuticals
  • Ferring Pharmaceuticals
  • Forest Laboratories
  • Fractyl
  • Garmin
  • HLS Therapeutics
  • Ironwood
  • Ischemix
  • Janssen
  • Javelin
  • LEXICON
  • Lilly
  • Medtronic
  • Merck
  • Moderna
  • MyoKardia
  • NirvaMed
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Owkin
  • Pfizer
  • PhaseBio
  • PLx Pharma
  • Recardio
  • Regeneron
  • Reid Hoffman Foundation
  • Roche
  • Sanofi
  • Stasys
  • Synaptic
  • The Medicines Company
  • Youngene
  • 89bio
  • Elsevier
  • Abbott
  • Biotronik
  • CSI
  • Endotronix
  • St. Jude Medical
  • Philips
  • SpectraWAVE
  • Svelte
  • Vascular Solutions
  • American College of Cardiology
  • FlowCo
  • Abbott
  • Affluent Medical
  • Alleviant Medical
  • Amgen
  • BAIM
  • Beth Israel Deaconess Medical Center
  • Boston Scientific
  • Bristol-Myers Squibb
  • CardiaWave
  • Chiesi
  • Concept Medical
  • Daiichi Sankyo
  • Duke
  • Faraday
  • Idorsia
  • Janssen
  • MedAlliance
  • Medscape
  • Mediasphere
  • Medtelligence
  • Novartis
  • Pi-Cardia
  • Protembis
  • RM Global Bioaccess Fund Management
  • Sanofi
  • Affluent Medical
  • Boehringer Ingelheim
  • Chiesi USA
  • Cordis
  • Esperion Science
  • Innovative BioPharma
  • IQVIA
  • Medscape
  • WebMD Global
  • PeerView Institute for Medical Education
  • Radcliffe
  • Elixir Medical
  • STEL
  • ControlRad
  • SCAI
  • Faculty Cardiovascular Research Foundation
  • JAMA Cardiology
  • ACC

This publication has 36 references indexed in Scilit: